Transcatheter aortic valve implantation with the new-generation Evolut R™
| Autor: | Thomas Münzel, Eberhard Schulz, Alexander Jabs, Christian F. Vahl, Stephan von Bardeleben, Tommaso Gori, Walter Kasper-König, Ulrich Hink |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
CoreValve®
medicine.medical_specialty lcsh:Diseases of the circulatory (Cardiovascular) system Transcatheter aortic medicine.medical_treatment Regurgitation (circulation) 030204 cardiovascular system & hematology Single Center Prosthesis 03 medical and health sciences 0302 clinical medicine Internal medicine medicine 030212 general & internal medicine Heart valve Asystole Transcatheter aortic valve implantation business.industry medicine.disease Surgery Evolut R™ Paravalvular leak medicine.anatomical_structure lcsh:RC666-701 Cohort Cardiology Cardiology and Cardiovascular Medicine business Atrioventricular block |
| Zdroj: | International Journal of Cardiology: Heart & Vasculature, Vol 12, Iss C, Pp 52-56 (2016) |
| ISSN: | 2352-9067 |
| DOI: | 10.1016/j.ijcha.2016.06.002 |
| Popis: | Background The Medtronic Evolut R (EVR) is a novel transcatheter heart valve designed to allow precise implantation at the intended position and to minimize prosthesis dysfunction as well as procedural complications. Our aim was to compare short-term functional and clinical outcomes of the new EVR with the established Medtronic CoreValve (CV) system. Methods and results Of 151 patients undergoing transfemoral transcatheter aortic valve implantation with a self-expanding valve at our institution between January 2013 and January 2016, 86 were treated with EVR and 65 with CV. Patients treated with EVR had a significantly lower rate of more-than-mild aortic regurgitation and a higher rate of device success. Recapture maneuvers to optimize valve deployment were performed in 22.1% of the EVR procedures. Transvalvular post-procedural gradients were slightly higher in the EVR group, while no differences were observed in the incidence of safety endpoints at 30 days, vascular complications, or need for permanent pacemaker implantation following asystole or complete atrioventricular block. Conclusions These initial single-center experience data on the short-term outcomes after EVR valve implantation show a substantially reduced rate of more-than-mild paravalvular regurgitation and higher device success, while 30-day safety outcomes were similar to the CV system. Clinical outcome data from long-term follow-up and larger scale multicenter experience are now necessary. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|